Biotechnology News and Research

RSS

K-PAX Pharmaceuticals works with Stanford University to identify effective treatment for chronic fatigue

K-PAX Pharmaceuticals is working with Stanford University and several other leading research institutions to perform a Phase II double-blind, placebo-controlled trial to evaluate the safety and efficacy of a currently available FDA-approved medication concurrently administered with a novel mitochondrial support product in order to identify a safe and effective treatment for the chronic fatigue and decreased alertness (i.e. brain fog) that commonly afflicts people with CFS.

26 Feb 2014

QIAGEN launches careHPV Test in India for prevention of cervical cancer among women

QIAGEN N.V. today announced the commercial launch in India of its careHPV™ Test, the only molecular diagnostic for high-risk human papillomavirus (HPV) designed to screen women in settings with limited healthcare infrastructure, such as areas lacking electricity, water or laboratories.

From QIAGEN Manchester Limited 26 Feb 2014

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA.

26 Feb 2014

European Commission invests nearly $475 million in gene transfer and gene therapy projects

Over the past three funding stages, the European Commission has invested nearly $475 million in 100 projects in the gene transfer and gene therapy field.

25 Feb 2014

PDL BioPharma releases fourth quarter and full year 2013 financial results for period ended 2013

PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2013 financial results for the period ended December 31, 2013, on Monday, March 3, 2014, after market close.

24 Feb 2014

Research explains how cells behave when placed in low oxygen environment

Research at the University of Liverpool has explained how cells behave when placed in a low oxygen environment, a development that could have implications for cancer patients and other serious illnesses.

24 Feb 2014

Study links carbohydrate calorie-rich diets to greater risk for brain shrinkage, dementia and AD

Even small increases in blood sugar caused by a diet high in carbohydrates can be detrimental to brain health. Recent reports in medical literature link carbohydrate calorie-rich diets to a greater risk for brain shrinkage, dementia and Alzheimer's disease, impaired cognition, and other disorders.

24 Feb 2014

Rapid advances and potential in 3D printing and additive manufacturing technologies

A new era of manufacturing is upon us. Recent developments in 3D printing and additive manufacturing technologies are set to usher in the next generation of industrial competitiveness.

23 Feb 2014

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has completed dosing of its Phase 2 clinical trial of GCS-100 for the treatment of chronic kidney disease ("CKD") and has collected the final data for evaluation of the primary endpoint.

23 Feb 2014

Study determines effectiveness of gabapentin for treatment of vulvodynia in women

A chronic syndrome called vulvodynia that affects from four to seven percent of women is being studied by physicians at The Women's Health Institute at Robert Wood Johnson Medical School, part of Rutgers, The State University of New Jersey, in hopes of alleviating sometimes excruciating pain.

21 Feb 2014

Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101

Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

21 Feb 2014

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

CardioCell LLC announces two new clinical trials using its allogeneic stem-cell therapy to treat subjects with acute myocardial infarction (AMI), a problem facing more than 1.26 million Americans annually.

20 Feb 2014

Researcher receives Pioneer Award for engineering herpes simplex virus gene delivery systems

Joseph C. Glorioso, III, PhD (University of Pittsburgh School of Medicine, PA) devoted much of his research career to developing herpes viruses as efficient vectors for delivering therapeutic genes into cells.

20 Feb 2014

PAREXEL announces launch of new regulatory outsourcing service line for life sciences industry

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of a new service line designed to provide a focused, market-driven approach to regulatory outsourcing services in the life sciences industry, with a primary emphasis on post-approval regulatory activities.

From Parexel 19 Feb 2014

Chronic intake of marijuana protects critical immune tissue from damaging effects of HIV infection

New evidence that chronic intake of THC, the primary psychoactive ingredient in marijuana, can protect critical immune tissue in the gut from the damaging effects of HIV infection is reported in AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

19 Feb 2014

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

By 2020, nearly 80 million people are expected to have glaucoma, a disorder of the eye that, if left untreated, can damage the optic nerve and eventually lead to blindness.

19 Feb 2014

Scientists produce reliable set of genotypes to benchmark human genome sequencing

Led by biomedical engineer Justin Zook of the National Institute of Standards and Technology, a team of scientists from Harvard University and the Virginia Bioinformatics Institute of Virginia Tech has presented new methods to integrate data from different sequencing platforms, thus producing a reliable set of genotypes to benchmark human genome sequencing.

19 Feb 2014

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

19 Feb 2014

The Future of DNA Sequencing

In this interview, Barret Bready discusses the current gold standards in DNA sequencing and how the Nabsys platform is revolutionizing this process.

18 Feb 2014

Bioline enters Epigenetics field with launch of new EPIK product range

Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc., announces that it has entered the rapidly growing Epigenetics field, with the launch of the first kits in the new EPIK™ product range; EPIK™ Fast Quantification Kit and EPIK™ Amplification Kit.

18 Feb 2014

Biotechnology News and Research

K-PAX Pharmaceuticals works with Stanford University to identify effective treatment for chronic fatigue

QIAGEN launches careHPV Test in India for prevention of cervical cancer among women

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

European Commission invests nearly $475 million in gene transfer and gene therapy projects

PDL BioPharma releases fourth quarter and full year 2013 financial results for period ended 2013

Research explains how cells behave when placed in low oxygen environment

Study links carbohydrate calorie-rich diets to greater risk for brain shrinkage, dementia and AD

Rapid advances and potential in 3D printing and additive manufacturing technologies

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

Study determines effectiveness of gabapentin for treatment of vulvodynia in women

Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

Researcher receives Pioneer Award for engineering herpes simplex virus gene delivery systems

PAREXEL announces launch of new regulatory outsourcing service line for life sciences industry

Chronic intake of marijuana protects critical immune tissue from damaging effects of HIV infection

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

Scientists produce reliable set of genotypes to benchmark human genome sequencing

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

The Future of DNA Sequencing

Bioline enters Epigenetics field with launch of new EPIK product range

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News